P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
ConditionHelicobacter Pylori Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorYueyue Li
About this trial
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients aged 18-70 years, regardless of gender;
willing to receive H. pylori eradication therapy;
diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.
Disqualifiers
patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.
Trial population
(1) patients aged 18-70 years, regardless of gender; (2) willing to receive H. pylori eradication therapy; (3) diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstances，not involve any intervention procedures
Other interventionDoctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstances，not involve any intervention procedures.
Treatment groups
1,730 Participants
are divided into 2 treatment groupsGroup A: vonoprazan-based quadruple therapies1 intervention
Group B: tegoprazan-based quadruple therapies1 intervention
Trial outcomes
Primary outcomes
1
Eradication rate
Comparison of eradication rates among quadruple therapies for Helicobacter pylori
Time frame
6-8 weeks after treatment completionSecondary outcomes
1
Adverse events
Time frame
lmmediately after treatment completionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Yueyue Li
Lead sponsor
Qilu Hospital of Shandong University
Sponsor institution
Qilu Hospital of Shandong University
Collaborator
Feicheng People's Hospital
Collaborator
Binzhou Maternal and Child Health Hospital
Collaborator
Jinxiang County People's Hospital
Collaborator
The People's Hospital of Jimo
Collaborator
Zibo Maternal and Child Health Hospital
Collaborator
Yantai Penglai Traditional Chinese Medicine Hospital
Collaborator
Zaozhuang Municipal Hospital
Collaborator
Linyi Yizhou Hospital
Collaborator
Taierzhuang District People's Hospital
Collaborator
Shandong University of Traditional Chinese Medicine
Collaborator
Yuncheng Traditional Chinese Medicine Hospital
Collaborator
Caoxian County Hospital
Collaborator
Qihe County People's Hospital
Collaborator
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Collaborator
Dezhou Hospital Qilu Hospital of Shandong University
Collaborator
Dongying No. 2 People's Hospital
Collaborator
Zhangdian District Hospital of Traditional Chinese Medicine
Collaborator
Yantai Zhifu Hospital
Collaborator
Inner Mongolia People's Hospital
Collaborator
Hohhot Second Hospital
Collaborator
Guanxian County People's Hospital
Collaborator
Longkou People's Hospital
Collaborator
Linshu County Hospital of Traditional Chinese Medicine
Collaborator
Source ClinicalTrials.gov